Results for: Edwards Lifesciences

Robbins Geller Rudman & Dowd LLP is representing investors who purchased Edwards Lifesciences Corporation (EW) securities between February 6, 2024 and July 24, 2024, in a class action lawsuit alleging that the company made false and misleading statements about its financial performance and prospects. The lawsuit claims that Edwards Lifesciences misrepresented the growth potential of its Transcatheter Aortic Valve Replacement (TAVR) product, leading to a significant stock price drop after the company announced disappointing second-quarter 2024 results. Investors who suffered losses during this period have until December 13, 2024, to seek appointment as lead plaintiff in the lawsuit.

Faruqi & Faruqi, LLP is investigating potential claims against Edwards Lifesciences Corporation (EW) for alleged securities law violations. The firm encourages investors who suffered losses exceeding $100,000 in Edwards between February 6, 2024, and July 24, 2024, to contact them directly. The lawsuit alleges that Edwards misled investors about the growth of its core product, Transcatheter Aortic Valve Replacement (TAVR), resulting in a significant stock price decline.